Literature DB >> 8704175

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

M L Disis1, H Bernhard, F M Shiota, S L Hand, J R Gralow, E S Huseby, S Gillis, M A Cheever.   

Abstract

The current studies evaluate granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant. An important issue for developing vaccine therapy for human malignancy is identifying adjuvants that can elicit T-cell responses to proteins and peptides derived from "self" tumor antigens. GM-CSF, in vitro, stimulates the growth of antigen-presenting cells such as dendritic cells and macrophages. Initial experiments examined whether GM-CSF injected into the skin of rats could affect the number or character of antigen presenting cells, measured as class II major histocompatability complex expressing cells, in lymph nodes draining the injection site. Intradermal (id) inoculation of GM-CSF every 24 hours for a total of five inoculations resulted in an increase of class II+ fluorescing cells that peaked at the fourth inoculation. Subcutaneous (sq) inoculation resulted in an increase of class II+ fluorescing cells that peaked following the second inoculation, then decreased over time. Using this schema for "conditioning" the inoculation site, GM-CSF was administered id or sq for five injections and a foreign antigen, tetanus toxoid (tt), was given at the beginning or the end of the immunization cycle. Id immunization was more effective than sq at eliciting tt specific immunity. In addition, GM-CSF id, administered as a single dose with antigen, compared favorably with complete Freund's adjuvant (CFA) and alum in eliciting tt specific antibody and cellular immunity. We have shown that immunity to rat neu (c-erbB-2) protein, an oncogenic self protein, can be generated in rats by immunization with peptides derived from the normal rat neu sequence plus CFA. The current study demonstrates that rat neu peptides inoculated with GM-CSF could elicit a strong delayed type hypersensitivity reaction (DTH) response, whereas peptides alone were non-immunogenic. GM-CSF was as effective as CFA in generating rat neu specific DTH responses after immunization with a neu peptide based vaccine. Soluble GM-CSF is a potent adjuvant for the generation of immune responses to foreign proteins as well as peptides derived from a self tumor antigen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704175

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

1.  New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.

Authors:  A J van den Eertwegh ; H M Pinedo
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice.

Authors:  I K Campbell; A Bendele; D A Smith; J A Hamilton
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

Review 3.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

4.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 5.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

6.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

7.  Hepatitis B immunization of healthy elderly adults: relationship between naïve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant.

Authors:  R J Looney; M S Hasan; D Coffin; D Campbell; A R Falsey; J Kolassa; J M Agosti; G N Abraham; T G Evans
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

Review 8.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

9.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 10.  Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

Authors:  Paul J Toren; Martin E Gleave
Journal:  Asian J Androl       Date:  2013-04-15       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.